A meta-analysis ordered by the agency and conducted by drugmaker Pfizer found a higher occurrence of major adverse cardiovascular events — including death, MI, and stroke — with the drug than with placebo.

The FDA noted, however, that such events were uncommon in both groups, and the increased risk wasn’t statistically significant.

via Chantix May Up Heart Risk, FDA Warns.

Quitting smoking is good.  Maybe quitting smoking without a pharmaceutical assist is better.  Additional link to the FDA release follows.

Safety Alerts for Human Medical Products > Chantix (Varenicline): Safety Communication – Updated Safety Review On The Risk of Cardiovascular Adverse Events.